Emmanuel Antonarakis, MD
Enriched profileClark Endowed Professor of Medicine; Director of Genitourinary Oncology, Division of Hematology, Oncology and Transplantation, Department of Medicine · University of Minnesota Medical School
Emmanuel Antonarakis is Clark Endowed Professor of Medicine; Director of Genitourinary Oncology, Division of Hematology, Oncology and Transplantation, Department of Medicine at University of Minnesota Medical School. OpenAlex indexes 1,495 publications with 36,361 citations (h-index 83); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 21 Sept 2026
Overview
Updated 14 Oct 2026
Emmanuel Antonarakis, M.D., is Clark Endowed Professor of Medicine at University of Minnesota Medical School (Masonic Cancer Center). The public record shows 1,495 publications with 36,361 citations (h-index 83), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 23 companies, 1 NIH-funded awards (2026–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Prostate Cancer Treatment and Research
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 88 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 361.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Sponsor: Masonic Cancer Center, University of Minnesota
- Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Industry payments
Updated 14 Oct 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Bayer Healthcare Pharmaceuticals Inc.Program year202517 payments$12,723openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20252 payments
- Merck Sharp & Dohme LLCProgram year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
48.9%Anti-androgens13.9%Nubeqa100%Part D<11 patientsCytochrome P450 17A1 Inhibitor12.5%Abiraterone Acetate100%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
28%Corticosteroid21.5%Prednisone100%Part D≥23 patientsSerotonin-3 Receptor Antagonist6.6%Ondansetron Odt58%Ondansetron Hcl42%Part D<11 patientsCardiovascular
7.8%Statin5%Rosuvastatin Calcium52%Atorvastatin Calcium48%Part D<11 patientsACE inhibitor2.8%Lisinopril100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
- Mayo Clinic / University of Minnesota Prostate SPORE
Mayo Clinic Rochester
FY2026$2,235,791P50CA298941 - Targeting TP53-altered castration-resistant prostate cancer with bipolar androgen therapy (BAT) plus carboplatin.
Mayo Clinic Rochester
FY2026$417,554P50CA298941 - The aberrant androgen receptor underlies abiraterone/enzalutamide resistance
Johns Hopkins University
FY2018$370,575R01CA185297
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study.
Clinical cancer research
Clinical Trial2026 - Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.
Clinical cancer research
Clinical Trial2026 - Integrated Single-Cell Profiling Reveals Dichotomous NK Cell Populations Associated with Immunosuppression in Solid Tumors.
Cancer immunology research
Article2026 - Molecular Characterization of KLK2 RNA Expression in Prostate Cancer.
Clinical cancer research
Article2026 - HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer.
Prostate cancer and prostatic diseases
Article2026
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/emmanuel-antonarakis-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/emmanuel-s-antonarakis-m-d-854a4b13
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/EAntonarakis
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
Mentions by others
where others cite or feature them- Other
cancer.umn.edu/news/dr-emmanuel-antonarakis-named-masonic-cancer-center-associate-director-translational-research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.umn.edu ↗ - Other
cancer.umn.edu/staff/emmanuel-antonarakis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.umn.edu ↗ - Other
experts.umn.edu/en/persons/emmanuel-antonarakis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →experts.umn.edu ↗ - Other
med.umn.edu/bio/emmanuel-antonarakis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.umn.edu ↗ - LinkedIn
LinkedIn profile: 'Director of GU Oncology, Associate Director for Translation[al Research]'
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Wales College of Medicine, Cardiff, Wales, UK
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.umn.edu ↗ - Internship
University Hospital of Wales, Cardiff, Wales, UK
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.umn.edu ↗ - Residency in Internal Medicine
Johns Hopkins Bayview Medical Center, Baltimore, MD
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.umn.edu ↗ - Fellowship in Medical Oncology
Johns Hopkins Hospital, Baltimore, MD
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.umn.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.umn.edu ↗
Editorial & leadership roles
journal and society appointments- Member
ASCO Educational Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.umn.edu ↗ - Member
NCI Prostate Cancer Task Force
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.umn.edu ↗ - Active in National Comprehensive Cancer Network (NCCN)
ECOG-ACRIN Cooperative Group, and Prostate Cancer Clinical Trials Consortium
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.umn.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.umn.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →the-asci.org ↗
- Recipient of multiple (unnamed) awards for translational research and teaching
per Masonic Cancer Center announcement
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.umn.edu ↗
Secondary affiliations
appointments beyond the home institution- Associate Director for Translational Research
Masonic Cancer Center, University of Minnesota
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.umn.edu ↗ - Genitourinary medical oncologist
M Health Fairview (University of Minnesota Medical Center / Southdale Hospital)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Formerly Professor of Oncology and Urology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Director of Prostate Cancer Medical Oncology Research and Co-Director …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.umn.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urologytimes.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →videopodcast.researchtopractice.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjoncology.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →grandroundsinurology.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Daniel Weisdorf, MD
University of Minnesota Medical School
Jeffrey Miller, MD
University of Minnesota Medical School
David Boulware, MD, MPH
University of Minnesota Medical School
Jerrold Vitek, MD
University of Minnesota Medical School
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)